×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. We are committed to safeguarding your information and ensuring the highest standards of data protection. Your trust and privacy are of utmost importance to us.

US FDA expands indications for brivaracetam and eslicarbazepine

  530 Views

eMediNexus    19 September 2017

The US FDA has expanded the indications for two anti-epileptic drugs, brivaracetam and eslicarbazepine. Brivaracetam is now approved as monotherapy for partial-onset seizures in epilepsy patients aged 16 years and older. Eslicarbazepine is now approved to treat partial-onset seizures in children and adolescents aged 4 to 17 years.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.